216 related articles for article (PubMed ID: 16787364)
1. Antiestrogenically active 2-benzyl-1,1-diarylbut-2-enes: synthesis, structure-activity relationships and molecular modeling study for flexible estrogen receptor antagonists.
Lloyd DG; Smith HM; O'Sullivan T; Knox AS; Zisterer DM; Meegan MJ
Med Chem; 2006 Mar; 2(2):147-68. PubMed ID: 16787364
[TBL] [Abstract][Full Text] [Related]
2. Synthesis, structure-activity relationships and antagonistic effects in human MCF-7 breast cancer cells of flexible estrogen receptor modulators.
Lloyd DG; Smith HM; O'Sullivan T; Zisterer DM; Meegan MJ
Med Chem; 2005 Jul; 1(4):335-53. PubMed ID: 16789891
[TBL] [Abstract][Full Text] [Related]
3. Flexible estrogen receptor modulators: synthesis, biochemistry and molecular modeling studies for 3-benzyl-4,6-diarylhex-3-ene and 3,4,6-triarylhex-3-ene derivatives.
Smith HM; Knox AJ; Zisterer DM; Lloyd DG; Meegan MJ
Med Chem; 2007 Mar; 3(2):135-55. PubMed ID: 17348852
[TBL] [Abstract][Full Text] [Related]
4. Flexible estrogen receptor modulators: design, synthesis, and antagonistic effects in human MCF-7 breast cancer cells.
Meegan MJ; Hughes RB; Lloyd DG; Williams DC; Zisterer DM
J Med Chem; 2001 Mar; 44(7):1072-84. PubMed ID: 11297454
[TBL] [Abstract][Full Text] [Related]
5. Structure-function relationships of the raloxifene-estrogen receptor-alpha complex for regulating transforming growth factor-alpha expression in breast cancer cells.
Liu H; Park WC; Bentrem DJ; McKian KP; Reyes Ade L; Loweth JA; Schafer JM; Zapf JW; Jordan VC
J Biol Chem; 2002 Mar; 277(11):9189-98. PubMed ID: 11751902
[TBL] [Abstract][Full Text] [Related]
6. Estrogen receptor beta activates the human retinoic acid receptor alpha-1 promoter in response to tamoxifen and other estrogen receptor antagonists, but not in response to estrogen.
Zou A; Marschke KB; Arnold KE; Berger EM; Fitzgerald P; Mais DE; Allegretto EA
Mol Endocrinol; 1999 Mar; 13(3):418-30. PubMed ID: 10076999
[TBL] [Abstract][Full Text] [Related]
7. The enhanced antiproliferative response to combined treatment of trichostatin A with raloxifene in MCF-7 breast cancer cells and its relevance to estrogen receptor β expression.
Tu Z; Li H; Ma Y; Tang B; Tian J; Akers W; Achilefu S; Gu Y
Mol Cell Biochem; 2012 Jul; 366(1-2):111-22. PubMed ID: 22476901
[TBL] [Abstract][Full Text] [Related]
8. Development of the β-lactam type molecular scaffold for selective estrogen receptor α modulator action: synthesis and cytotoxic effects in MCF-7 breast cancer cells.
Carr M; Knox AJ; Lloyd DG; Zisterer DM; Meegan MJ
J Enzyme Inhib Med Chem; 2016; 31(sup3):117-130. PubMed ID: 27476825
[TBL] [Abstract][Full Text] [Related]
9. Carboxylic acid analogues of tamoxifen: (Z)-2-[p-(1, 2-diphenyl-1-butenyl)phenoxy]-N,N-dimethylethylamine. Estrogen receptor affinity and estrogen antagonist effects in MCF-7 cells.
Kraft KS; Ruenitz PC; Bartlett MG
J Med Chem; 1999 Aug; 42(16):3126-33. PubMed ID: 10447957
[TBL] [Abstract][Full Text] [Related]
10. Molecular mechanisms of estrogen action: selective ligands and receptor pharmacology.
Katzenellenbogen BS; Choi I; Delage-Mourroux R; Ediger TR; Martini PG; Montano M; Sun J; Weis K; Katzenellenbogen JA
J Steroid Biochem Mol Biol; 2000 Nov; 74(5):279-85. PubMed ID: 11162936
[TBL] [Abstract][Full Text] [Related]
11. Novel Selective Estrogen Receptor Ligand Conjugates Incorporating Endoxifen-Combretastatin and Cyclofenil-Combretastatin Hybrid Scaffolds: Synthesis and Biochemical Evaluation.
Kelly PM; Keely NO; Bright SA; Yassin B; Ana G; Fayne D; Zisterer DM; Meegan MJ
Molecules; 2017 Aug; 22(9):. PubMed ID: 28858267
[TBL] [Abstract][Full Text] [Related]
12. Structural basis for the deactivation of the estrogen-related receptor gamma by diethylstilbestrol or 4-hydroxytamoxifen and determinants of selectivity.
Greschik H; Flaig R; Renaud JP; Moras D
J Biol Chem; 2004 Aug; 279(32):33639-46. PubMed ID: 15161930
[TBL] [Abstract][Full Text] [Related]
13. Synthesis and biological evaluation of novel cyclopropyl derivatives as subtype-selective ligands for estrogen receptor.
Wang Z; Yang Y; Zheng X; Zhang T; Huang W; Yan D; Zhang W; Wang X; Shen Z
J Pharm Pharmacol; 2018 Jul; 70(7):910-918. PubMed ID: 29582419
[TBL] [Abstract][Full Text] [Related]
14. Identification of putative estrogen receptor-mediated endocrine disrupting chemicals using QSAR- and structure-based virtual screening approaches.
Zhang L; Sedykh A; Tripathi A; Zhu H; Afantitis A; Mouchlis VD; Melagraki G; Rusyn I; Tropsha A
Toxicol Appl Pharmacol; 2013 Oct; 272(1):67-76. PubMed ID: 23707773
[TBL] [Abstract][Full Text] [Related]
15. Benzothiepin-derived molecular scaffolds for estrogen receptor modulators: synthesis and antagonistic effects in breast cancer cells.
Meegan MJ; Barrett I; Zimmermann J; Knox AJ; Zisterer DM; Lloyd DG
J Enzyme Inhib Med Chem; 2007 Oct; 22(5):655-66. PubMed ID: 18035834
[TBL] [Abstract][Full Text] [Related]
16. Design and synthesis of novel flexible ester-containing analogs of tamoxifen and their evaluation as anticancer agents.
Elghazawy NH; Engel M; Hartmann RW; Hamed MM; Ahmed NS; Abadi AH
Future Med Chem; 2016; 8(3):249-56. PubMed ID: 26898104
[TBL] [Abstract][Full Text] [Related]
17. Effects of 4-hydroxytamoxifen, raloxifene and ICI 182 780 on survival of uterine cancer cell lines in the presence and absence of exogenous estrogens.
Leblanc K; Sexton E; Parent S; Bélanger G; Déry MC; Boucher V; Asselin E
Int J Oncol; 2007 Feb; 30(2):477-87. PubMed ID: 17203231
[TBL] [Abstract][Full Text] [Related]
18. Synthesis, biological evaluation, structural-activity relationship, and docking study for a series of benzoxepin-derived estrogen receptor modulators.
Barrett I; Meegan MJ; Hughes RB; Carr M; Knox AJ; Artemenko N; Golfis G; Zisterer DM; Lloyd DG
Bioorg Med Chem; 2008 Nov; 16(21):9554-73. PubMed ID: 18835176
[TBL] [Abstract][Full Text] [Related]
19. Antiestrogenic potency and binding characteristics of the triphenylethylene H1285 in MCF-7 human breast cancer cells.
Sheen YY; Ruh TS; Mangel WF; Katzenellenbogen BS
Cancer Res; 1985 Sep; 45(9):4192-9. PubMed ID: 4040807
[TBL] [Abstract][Full Text] [Related]
20. Raloxifene inhibits growth of RT4 urothelial carcinoma cells via estrogen receptor-dependent induction of apoptosis and inhibition of proliferation.
Hoffman KL; Lerner SP; Smith CL
Horm Cancer; 2013 Feb; 4(1):24-35. PubMed ID: 22965848
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
